Getinge's 15.1% Margin Is on Loan From the Tariff Refund Desk
A quarter that looks like a margin victory is mostly a refund timing story — the real earnings lever is parked in 2027 and management knows it
GETI-B.ST · Earnings Call · 2026-10-21
A quarter flattered by something finite
Getinge printed an adjusted EBITA of SEK 1.278 billion, a 15.1% margin, with adjusted gross margin up 2.2 percentage points. Strip out the accounting and the headline softens immediately: “adjusted gross profit amounted to SEK 4.343 billion in the quarter, primarily on the back of the factors I just mentioned, but also supported by the remaining tariff refund of approximately SEK 45 million” — Agneta Palmer, CFO · 2026-10-21. The operative word is "remaining." A refund is a finite asset, not a run-rate improvement. Management did the arithmetic for us on the very next slide: “even if excluding the tariff refund of SEK 381 million in Q2 and Q3 of 2026, we are at 14.5%” — Mattias Perjos, CEO · 2026-10-21. So the rolling-twelve-month improvement from 12% to 15.6% loses a full point when you remove a one-time cash-back event. That is the honest number, and it is the number the 16-19% by-2028 target has to be measured from. This is not a Getinge invention. Tariff refund was the single highest-momentum keyword in the entire market's curated set last quarter, and it is still reverberating through unrelated P&Ls a quarter later — a toymaker booked a benefit from tariff refunds, an investment company flagged refunds landing in its portfolio, an aerospace name talked about IEEPA recovery. A theme that shows up in a toy company and a holding company in the same week is a macro wave, not a competitive moat. Getinge is surfing it, not building it. The company's own remaining tariff refund phrasing is an admission that the wave is already receding.What management quietly stopped saying
Two things fell off the agenda this quarter, and both matter more than what was added. First, margin guidance — the top-ranked keyword on the Q2 2026 call — is now a decliner. Management killed it in January and has not revived it: “we are not going to do any margin guidance for 2026. We remain with the top line guidance only” — Mattias Perjos, CEO · 2026-04-21. When a company with a 16-19% long-term margin target will not put a floor under the current year, the market should read that as an absence of confidence, not modesty. Every analyst who asked about ACT margin trajectory got the same wall: CEO Mattias Perjos, flatly, "No, it's the short answer." Second, the Cardiohelp II launch narrative has been downgraded from catalyst to patience. It is live in CE countries and Hong Kong, but the U.S. ECMO 510(k) remains unsubmitted — the same answer for four straight quarters. In July: “the part that we can impact, which means the submissions of 510(k) applications, I think we're on top of that” — Mattias Perjos, CEO · 2026-07-17. In October: "No news. Really, we will communicate once it's been submitted." The launch of Cardiohelp II is real but slow; management explicitly warned that "the launch takes a while to really roll out properly." Meanwhile the intra-aortic balloon pump franchise stays capacity-constrained, with Perjos conceding the situation will remain "challenging for the remainder of this year as well." A remediation storyline that has run for years is still running.The real lever is a 2027 story wearing 2026 clothes
Here is the crux. Getinge's genuine, structural margin improvement — the thing that would justify the 16-19% span — is the step-down in quality cost. That keyword topped the company's own agenda back in Q1 2024, then steadily decayed as the costs stopped moving. This quarter the CFO was blunt that it is no longer a swing factor: “we are progressing on that trajectory that we have described before when it comes to quality cost, but it still remains elevated compared to sort of normal levels, and that will remain for some time” — Agneta Palmer, CFO · 2026-10-21. And the shape of the release is unchanged from July, when Perjos mapped it: “the SEK 800 million of extraordinary quality cost that we said peaked in 2024... a little bit of a rapid decrease of cost in 2027 and 2028” — Mattias Perjos, CEO · 2026-07-17. On this call he simply repeated the cadence — "definitely larger in '27 compared to '26, and then larger again in 2028." So the sequence is: 2026 is the refund year; 2027-28 is the quality-cost-release year. An investor buying today's 15.1% print as evidence of operating leverage is buying a bridge. The structural earnings power arrives after the refunds are gone.Q4 needs a hero, and the CFO won't name one
Year-to-date organic growth is 2.5% against a reiterated 3-5% guide, which means Q4 has to deliver roughly 4%. Analysts pressed hard on exactly what gets them there, and got deflection: "We don't disclose which categories we believe are most important when it comes to a specific quarter like this." Then, the tell:That is a soft warning dressed as continuity. The guidance span was not narrowed, and management cited delivery-timing risk — customers not ready to receive capital goods before year-end, shipments slipping into Q1. Note also that the 3-5% is stated "adjusted for the phaseout of Surgical Perfusion," a business shrinking from ~SEK 250 million to SEK 50 million this year — a structural ~50bp of reported-growth cosmetic that has been in place since early 2025. The offsetting bright spot is genuine: Surgical Workflows is now the company's top-ranked theme, with order intake buoyed by operating tables and lights. But Life Science remains a drag, with a fresh decline in washers, isolators and sterilizers offsetting strong Sterile Transfer — and Perjos admitted the capital-equipment part "is still sluggish," saved only by "a little bit better momentum in the U.S."The lower part of the guidance span is easier and much more realistic than the upper part.